Tumor-targeted astaxanthin nanoparticles for therapeutic application in vitro
Source abstract
Abstract
In recent years, with the development of molecular biology, the exploration and development of targeted drugs for cancer has gradually attracted widespread attention. Here, tumor-targeted astaxanthin nanoparticle, cRGD-PEG2000-DSPE encapsulated astaxanthin ([email protected]) was designed and applied for tumor therapy. Firstly, [email protected] can improve the water solubility of astaxanthin. Secondly, [email protected] can achieve tumor-targeted ability after cRGD modification and can be highly absorbed by HepG2 cells. Finally, [email protected] can scavenge excess ROS in tumor cells, restore the redox balance in cells, and inhibit tumor cell proliferation. It provides theoretical basis and experimental basis for the development and utilization of natural product antioxidants for cancer prevention and treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Application of artificial intelligence in the endoscopic diagnosis of early gastric cancer, atrophic gastritis, and helicobacter pylori infection10.1111/1751-2980.13154 ↗
2. Ferroptosis, free radicals, and cancer
3. Antioxidant activities of polysaccharides from the fruiting bodies of Zizyphus Jujuba cv Jinsixiaozao10.1016/j.carbpol.2010.11.051 ↗
4. Astaxanthin -king of antioxidants as immune modulator and anti-inflammatory for enhancing productive performance and health of animals10.33785/IJDS.2021.v74i01.001 ↗
5. Pharmaceutical and nutraceutical potential of natural bioactive pigment: astaxanthin10.1007/s13659-022-00347-y ↗
6. Research progress of Astaxanthin nano-based drug delivery system: applications, prospects and challenges?10.3389/fphar.2023.1102888 ↗
7. Research progress of astaxanthin
8. High-purity bioactive Ingredient-3 S,3’ S-Astaxanthin: a new preparation from genetically modified Kluyveromyces marxianus without column chromatography and gel filtration10.3390/antiox12040875 ↗
9. Astaxanthin anticancer effects are mediated through multiple molecular mechanisms: a systematic review10.1016/j.phrs.2020.104689 ↗
10. In vitro antitumor potential of astaxanthin nanoemulsion against cancer cells via mitochondrial mediated apoptosis10.1016/j.ijpharm.2019.02.015 ↗
11. Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery10.2165/00003088-200847100-00001 ↗
12. Targeting the molecular effects of a hypoxic tumor microenvironment10.2741/2372 ↗
13. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize10.1002/jcb.21187 ↗
14. The use of alternative strategies for enhanced nanoparticle delivery to solid tumors10.1021/acs.chemrev.0c00779 ↗
15. Interaction between PEG lipid and DSPE/DSPC phospholipids: An insight of PEGylation degree and kinetics of de-PEGylation10.1016/j.colsurfb.2017.04.018 ↗
16. DSPE-PEG: a distinctive component in drug delivery system10.2174/1381612821666150115144003 ↗
17. Probing adsorption of DSPE-PEG2000 and DSPE-PEG5000 to the surface of felodipine and griseofulvin nanocrystals10.1016/j.ijpharm.2016.06.046 ↗
18. Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS10.1111/jphp.12598 ↗
19. Characterization of 1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[Methoxy(polyethylene glycerol)-2000] and its complex with doxorubicin using nuclear magnetic resonance spectroscopy and molecular dynamics10.1021/acs.bioconjchem.7b00238 ↗
20. Infrared spectroscopy reveals the nonsynchronicity phenomenon in the glassy to fluid micellar transition of DSPE-PEG2000 aqueous dispersions10.1021/la101539z ↗
21. Cancer nanother-anostics: a review of the role of conjugated ligands for overexpressed receptors10.1016/j.ejps.2017.04.005 ↗
22. Nano-targeting of Thyrointegrin αvβ3 receptor in solid tumors and impact on Radiosensitization10.1667/RADE-21-00031.1 ↗
23. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation10.2174/187152010794728639 ↗
24. Recent progress in biomedical applications of RGD-based ligand: from precise cancer theranostics to biomaterial engineering: a systematic review10.1002/jbm.a.36862 ↗
25. Engineered nanomedicines with enhanced tumor penetration10.1016/j.nantod.2019.100800 ↗
26. Promoted delivery of Salinomycin to lung Cancer through epidermal growth factor receptor aptamers coupled DSPE-PEG2000 Nanomicelles10.1166/jnn.2018.15424 ↗
27. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells10.1016/j.jconrel.2017.06.021 ↗
28. Co-delivery of doxorubicin and curcumin via cRGD-peptide modified PEG-PLA self-assembly nanomicelles for lung cancer therapy10.1016/j.cclet.2021.11.076 ↗
29. Integrin alphabeta targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides
30. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting10.1016/j.colsurfb.2015.03.046 ↗
31. RGD peptide-Pegylated PLLA nanoparticles containing Epirubicin hydrochloride exhibit receptor-dependent tumor trafficking in vitro and in vivo10.1007/s11095-015-1625-2 ↗
32. Evaluation of alphanubeta3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo
33. Cyclic RGD peptides incorporating cycloalkanes: synthesis and evaluation as PET radiotracers for tumor imaging10.1021/ml500135t ↗
34. Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery10.1016/j.biomaterials.2014.05.021 ↗
35. Construction of a tumor cell-targeting non-viral gene delivery vector with polyethylenimine modified with RGD sequence containing peptide10.3892/ol.2013.1717 ↗
36. Kidney-targeted astaxanthin natural antioxidant nanosystem for diabetic nephropathy therapy10.1016/j.ejpb.2020.09.005 ↗
37. Astaxanthin: a super antioxidant from microalgae and its therapeutic potential10.1002/jobm.202100391 ↗
38. Astaxanthin supplementation delays physical exhaustion and prevents redox imbalances in plasma and soleus muscles of Wistar rats10.3390/nu6125819 ↗